| Literature DB >> 30235544 |
Masayo Oishi1, Shintaro Hiro1, Nobushige Matsuoka1, Shinichi Hotta1, Ryosuke Ono1, Yuko Mori1, Nobuko Takenaka1, Yoko Uchikawa1, Akio Arakawa1, Hirotoshi Yuasa1, Taro Ishibashi1, So Miyoshi1, Kanji Hirai1, Norisuke Kawai1.
Abstract
Global clinical studies conducted in various countries and regions are increasing. Race and extrinsic ethnic factors are key covariates that may affect the pharmacokinetics (PK), efficacy, and safety of the drug. Genetic similarity among East Asian populations has been confirmed; thus, PK, efficacy, and safety in these populations are expected to be similar, but this has not been confirmed. This study presents a comparison of PK and safety among East Asians from clinical studies sponsored by Pfizer. Four compounds with different characteristics, including mechanism of actions and PK profiles, were selected, and retrospective PK and safety comparisons in East Asians were conducted. No distinct differences were observed in PK and safety across the 4 compounds. These results are consistent with previous reports on PK comparisons and meet the expectations based on genetic similarity among East Asians. Extrapolation of these findings to other compounds should be done with caution, but these results should support the consideration of mutual use of clinical data among East Asian countries.Keywords: East Asia; bazedoxifene; crizotinib; ethnic difference; pharmacokinetics; safety; tolterodine; varenicline
Year: 2014 PMID: 30235544 DOI: 10.1177/2168479013517892
Source DB: PubMed Journal: Ther Innov Regul Sci ISSN: 2168-4790 Impact factor: 1.778